Eli Lilly is cracking down on knock-off versions of its popular weight loss drug ZepboundByBruce GilUpdatedJune 20, 2024
Netflix will open in-person 'experiences' at malls — but it won't use movie theatersByBruce GilUpdatedJune 18, 2024
CEO gets 6-year prison sentence over useless neurostimulator componentByBruce GilPublishedJune 18, 2024
Ozempic is now boosting sales for smaller-sized clothes, fashion executives sayByBruce GilUpdatedJune 17, 2024
Bernie Sanders will grill Novo Nordisk's CEO over Ozempic and Wegovy pricesByBruce GilPublishedJune 17, 2024
Netflix, Disney+ and 6 other streamers, ranked from the least content to the mostByBruce GilPublishedJune 17, 2024
Netflix, Disney+ and 6 other streamers, ranked from cheapest to most expensive right nowByBruce GilPublishedJune 16, 2024
Food companies worried about weight loss drugs can just make healthier food, Eli Lilly CEO saysByBruce GilPublishedJune 14, 2024
Eli Lilly wants to replace Zepbound with an even stronger weight loss drugByBruce GilPublishedJune 14, 2024
JPMorgan's Ozempic bet, J&J's baby powder settlement, Moderna's COVID-flu vax: Pharma news round upByBruce GilPublishedJune 14, 2024
JPMorgan is getting in on the Ozempic craze with a $500 million biotech fundByBruce GilUpdatedJune 13, 2024
Elizabeth Warren wants jail time for private equity execs who 'loot' hospitalsByBruce GilPublishedJune 12, 2024
Now playing Novo Nordisk could surpass LEGO as Denmark’s most valuable brand very soonPublishedJune 12, 2024
Johnson & Johnson will pay $700 million to settle talc baby powder caseByBruce GilPublishedJune 12, 2024
